What are the guidelines for managing Acute Respiratory Distress Syndrome (ARDS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Guidelines for Managing Acute Respiratory Distress Syndrome (ARDS)

The management of ARDS should follow a lung-protective strategy with low tidal volumes (4-8 mL/kg predicted body weight), low inspiratory pressures (plateau pressure ≤30 cmH2O), and appropriate PEEP based on ARDS severity. 1, 2

Definition and Classification

ARDS is characterized by:

  • Acute onset within one week of a known clinical insult
  • Bilateral opacities on chest imaging not fully explained by effusions, collapse, or nodules
  • Respiratory failure not explained by cardiac failure or fluid overload
  • Hypoxemia with PaO₂/FiO₂ ratio ≤300 mmHg with PEEP ≥5 cmH₂O

Severity classification:

  • Mild: PaO₂/FiO₂ 201-300 mmHg
  • Moderate: PaO₂/FiO₂ 101-200 mmHg
  • Severe: PaO₂/FiO₂ ≤100 mmHg

Core Management Strategies

1. Mechanical Ventilation (Strong Recommendations)

  • Lung-protective ventilation: Use tidal volumes of 4-8 mL/kg predicted body weight and maintain plateau pressure <30 cmH₂O 1
  • PEEP strategy:
    • Mild ARDS: Lower PEEP (5-10 cmH₂O)
    • Moderate to severe ARDS: Higher PEEP without prolonged recruitment maneuvers 1, 2
    • The 2024 ATS guideline strongly recommends against using prolonged lung recruitment maneuvers in moderate to severe ARDS 1

2. Adjunctive Therapies

  • Prone positioning: Strongly recommended for severe ARDS for >12 hours/day (ideally 16-20 hours), implemented early (within first 48 hours) 1, 2
  • Corticosteroids: Suggested for all ARDS patients to reduce inflammatory response and pulmonary edema 1, 2
  • Neuromuscular blocking agents: Suggested for early severe ARDS (first 48 hours) to prevent patient-ventilator dyssynchrony 1, 2
  • VV-ECMO: Suggested in selected patients with severe ARDS who fail conventional management 1
  • High-frequency oscillatory ventilation: Strongly recommended against routine use in moderate or severe ARDS 1

Management Algorithm Based on ARDS Severity

For All ARDS Patients:

  1. Implement lung-protective ventilation (4-8 mL/kg PBW, plateau pressure <30 cmH₂O)
  2. Consider systemic corticosteroids
  3. Use conservative fluid management strategy
  4. Provide DVT and stress ulcer prophylaxis
  5. Ensure appropriate nutritional support

For Moderate ARDS (PaO₂/FiO₂ 101-200 mmHg):

  • Implement higher PEEP strategy
  • Avoid prolonged recruitment maneuvers

For Severe ARDS (PaO₂/FiO₂ ≤100 mmHg):

  1. Implement higher PEEP strategy
  2. Initiate prone positioning for >12 hours/day
  3. Consider neuromuscular blockade for 48 hours
  4. For refractory hypoxemia, consider VV-ECMO in selected patients

Monitoring and Complications

  • Monitor for ventilator-associated pneumonia (occurs in 9-27% of intubated patients) 2
  • Watch for barotrauma, volutrauma, and atelectrauma 2
  • Assess daily for weaning readiness using spontaneous breathing trials 2

Prognosis

  • Hospital mortality for ARDS ranges from 30-45%, increasing with severity of hypoxemia 2
  • Survivors often experience decreased functional capacity, mental health issues, and reduced quality of life 3

Key Pitfalls to Avoid

  1. Excessive tidal volumes: Even in patients without ARDS, evidence suggests limiting tidal volumes is beneficial 4
  2. Inadequate PEEP: Zero PEEP is likely injurious; PEEP should be set to maximize alveolar recruitment while avoiding overdistention 4
  3. Delayed prone positioning: Early implementation (within 48 hours) is associated with better outcomes 2
  4. Fluid overload: Conservative fluid management is recommended to minimize pulmonary edema 2
  5. Prolonged recruitment maneuvers: These are now strongly recommended against in the 2024 ATS guideline 1

The 2024 American Thoracic Society guideline represents the most current evidence-based recommendations for ARDS management, updating previous guidelines with new recommendations on corticosteroids, VV-ECMO, neuromuscular blockers, and PEEP strategies 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Acute Respiratory Distress Syndrome (ARDS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.